339 related articles for article (PubMed ID: 15583654)
1. Recombinant protein therapeutics--success rates, market trends and values to 2010.
Pavlou AK; Reichert JM
Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654
[No Abstract] [Full Text] [Related]
2. Biotech drug market steadily expands.
Lawrence S
Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
[No Abstract] [Full Text] [Related]
3. Clinical development of therapeutic recombinant proteins.
Reichert JM; Paquette C
Biotechniques; 2003 Jul; 35(1):176-8, 180, 182-5. PubMed ID: 12866419
[TBL] [Abstract][Full Text] [Related]
4. Deconstructing Myogen's market cap.
Ransom J
Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
[No Abstract] [Full Text] [Related]
5. Biopharmaceuticals: recent approvals and likely directions.
Walsh G
Trends Biotechnol; 2005 Nov; 23(11):553-8. PubMed ID: 16051388
[TBL] [Abstract][Full Text] [Related]
6. The biotech drug market.
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
[No Abstract] [Full Text] [Related]
7. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002.
Reichert JM; Paquette C
Curr Opin Mol Ther; 2003 Apr; 5(2):139-47. PubMed ID: 12772503
[TBL] [Abstract][Full Text] [Related]
8. Trading on traditional medicines.
Basu P
Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941
[No Abstract] [Full Text] [Related]
9. Pipelines turn to biotech.
Lawrence S
Nat Biotechnol; 2007 Dec; 25(12):1342. PubMed ID: 18066015
[No Abstract] [Full Text] [Related]
10. Roche consolidates grip on anti-angiogenesis market.
Moran N
Nat Biotechnol; 2008 Oct; 26(10):1055-6. PubMed ID: 18846054
[No Abstract] [Full Text] [Related]
11. The latest trends in the pharmaceutical market.
Teitelbaum F
Case Manager; 2000; 11(5):70-4. PubMed ID: 11935588
[No Abstract] [Full Text] [Related]
12. Market watch: upcoming market catalysts in Q3 2012.
Jeng R
Nat Rev Drug Discov; 2012 Jun; 11(7):508. PubMed ID: 22743969
[No Abstract] [Full Text] [Related]
13. A change in the market--investing in diagnostics.
Batchelder K; Miller P
Nat Biotechnol; 2006 Aug; 24(8):922-6. PubMed ID: 16900131
[No Abstract] [Full Text] [Related]
14. Market watch: Upcoming catalysts in Q3 2014.
Haggerty R
Nat Rev Drug Discov; 2014 Jul; 13(7):486. PubMed ID: 24981351
[No Abstract] [Full Text] [Related]
15. Success rates for new drugs entering clinical testing in the United States.
DiMasi JA
Clin Pharmacol Ther; 1995 Jul; 58(1):1-14. PubMed ID: 7628176
[No Abstract] [Full Text] [Related]
16. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
17. Biomanufacturing, from bust to boom...to bubble?
Thiel KA
Nat Biotechnol; 2004 Nov; 22(11):1365-72. PubMed ID: 15529157
[No Abstract] [Full Text] [Related]
18. Tysabri back on market.
Sheridan C
Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
[No Abstract] [Full Text] [Related]
19. Sending pharma better signals.
Avorn J
Science; 2005 Jul; 309(5735):669. PubMed ID: 16051753
[No Abstract] [Full Text] [Related]
20. Raising the game.
Nat Biotechnol; 2008 Feb; 26(2):137. PubMed ID: 18259155
[No Abstract] [Full Text] [Related]
[Next] [New Search]
